All In Biotech

Drug Trial Radar · NCT07700160

First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

Phase 1/2a Open-label Clinical Trial Evaluating VBC108, a CLDN18.2 and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Jul 7, 2029

Study completion Sep 17, 2029

Sponsor

Lead sponsor
VelaVigo Bio IncIndustry
Sponsor type
Industry
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC108.

Conditions

  • Advanced Solid Tumors

Interventions

  • VBC108Drug

    VBC108

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: From time of first dose of VBC108 to end of DLT period ( 21 days)
  2. Incidence of Serious Adverse EventsTime frame: From time of Informed Consent to 30 days post last dose of VBC108
  3. Incidence of Adverse Events (AEs)Time frame: From time of Informed Consent to 30 days post last dose of VBC108
  4. Objective Response Rate (ORR)Time frame: From first dose of VBC108 to disease progression or death, up to approximately 2 years

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California · Recruiting

  • START Midwest, LLC

    Grand Rapids, Michigan · Recruiting

  • Laura and Issac Perlmutter Cancer Center

    New York, New York · Not yet recruiting

  • Next Oncology - Oncology

    San Antonio, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

  • GenesisCare North Shore

    St Leonards, New South Wales, Australia · Recruiting

  • One Clinical Research

    Perth, Western Australia, Australia · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Zhongshan Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.